Acute graft-versus-host disease is a major problem in allogeneic bone-marrow transplantation. We performed a randomized study to compare the effectiveness of two regimens in the prevention of acute graft-versus-host disease. Thirty-five patients received methotrexate alone, and 32 received methotrexate, antithymocyte globulin, and prednisone. Of the patients who received methotrexate alone, 48 per cent had acute graft-versus-host disease, as compared with 21 per cent of those who received methotrexate, antithymocyte globulin, and prednisone (P = 0.01). The age of the recipient was a significant factor in the development of acute graft-versus-host disease: Older patients had a higher incidence of the disease (P = 0.001). We conclude that the combination of methotrexate, antithymocyte globulin, and prednisone significantly decreased the incidence of acute graft-versus-host disease and should be used to prevent this disorder in patients receiving allogeneic marrow transplants.
This article has been cited by other articles:
Neudorf, S., Sanders, J., Kobrinsky, N., Alonzo, T. A., Buxton, A. B., Gold, S., Barnard, D. R., Wallace, J. D., Kalousek, D., Lange, B. J., Woods, W. G.
(2004). Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood
103: 3655-3661
[Abstract][Full Text]
Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P. E., di Bartolomeo, P., Oneto, R., Bruno, B., Barbanti, M., Sacchi, N., Van Lint, M. T., Bosi, A.
(2001). Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood
98: 2942-2947
[Abstract][Full Text]
Deeg, H. J., Shulman, H. M., Anderson, J. E., Bryant, E. M., Gooley, T. A., Slattery, J. T., Anasetti, C., Fefer, A., Storb, R., Appelbaum, F. R.
(2000). Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood
95: 1188-1194
[Abstract][Full Text]
Deeg, H. J., Lin, D., Leisenring, W., Boeckh, M., Anasetti, C., Appelbaum, F. R., Chauncey, T. R., Doney, K., Flowers, M., Martin, P., Nash, R., Schoch, G., Sullivan, K. M., Witherspoon, R. P., Storb, R.
(1997). Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. Blood
89: 3880-3887
[Abstract][Full Text]
Goulmy, E., Schipper, R., Pool, J., Blokland, E., Falkenburg, F., Vossen, J., Gratwohl, A., Vogelsang, G. B., van Houwelingen, H. C., van Rood, J. J.
(1996). Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow Transplantation. NEJM
334: 281-285
[Abstract][Full Text]
Armitage, J. O.
(1994). Bone Marrow Transplantation. NEJM
330: 827-838
[Full Text]
Chao, N. J., Schmidt, G. M., Niland, J. C., Amylon, M. D., Dagis, A. C., Long, G. D., Nademanee, A. P., Negrin, R. S., O'Donnell, M. R., Parker, P. M., Smith, E. P., Snyder, D. S., Stein, A. S., Wong, R. M., Blume, K. G., Forman, S. J.
(1993). Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host Disease. NEJM
329: 1225-1230
[Abstract][Full Text]
Shannon, K. M., Cowan, M. J., Matthay, K. K.
(1987). Pediatric Bone Marrow Transplantation: Intensive Care Management. J Intensive Care Med
2: 328-344
[Abstract]
Previous
